Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.57)
# 888
Out of 4,711 analysts
52
Total ratings
50%
Success rate
7.13%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Overweight | $165 → $160 | $134.51 | +18.95% | 6 | Nov 26, 2024 | |
| WAT Waters | Maintains: Neutral | $340 → $380 | $368.16 | +3.22% | 3 | Nov 4, 2024 | |
| TXG 10x Genomics | Maintains: Neutral | $20 → $14 | $14.04 | -0.28% | 2 | Oct 30, 2024 | |
| TMO Thermo Fisher | Maintains: Overweight | $650 → $670 | $524.05 | +27.85% | 8 | Sep 20, 2024 | |
| HSIC Henry Schein | Maintains: Overweight | $88 → $80 | $69.82 | +14.58% | 3 | Aug 12, 2024 | |
| NVST Envista Holdings | Downgrades: Neutral | $23 → $16 | $18.70 | -14.44% | 3 | Aug 8, 2024 | |
| TEM Tempus AI | Maintains: Overweight | $42 → $47 | $35.54 | +32.25% | 2 | Aug 7, 2024 | |
| MYGN Myriad Genetics | Maintains: Underweight | $17 → $20 | $13.36 | +49.70% | 3 | Aug 7, 2024 | |
| AKYA Akoya Biosciences | Downgrades: Neutral | n/a | $2.49 | - | 2 | Aug 6, 2024 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,300 → $1,400 | $1,230.74 | +13.75% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $6 | $6.39 | -6.10% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $200 | $144.46 | +38.45% | 4 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $120 | $112.56 | +6.61% | 3 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.97 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $57.00 | +57.89% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $228.55 | +18.14% | 4 | Dec 20, 2023 |
Agilent Technologies
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $134.51
Upside: +18.95%
Waters
Nov 4, 2024
Maintains: Neutral
Price Target: $340 → $380
Current: $368.16
Upside: +3.22%
10x Genomics
Oct 30, 2024
Maintains: Neutral
Price Target: $20 → $14
Current: $14.04
Upside: -0.28%
Thermo Fisher
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $524.05
Upside: +27.85%
Henry Schein
Aug 12, 2024
Maintains: Overweight
Price Target: $88 → $80
Current: $69.82
Upside: +14.58%
Envista Holdings
Aug 8, 2024
Downgrades: Neutral
Price Target: $23 → $16
Current: $18.70
Upside: -14.44%
Tempus AI
Aug 7, 2024
Maintains: Overweight
Price Target: $42 → $47
Current: $35.54
Upside: +32.25%
Myriad Genetics
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $13.36
Upside: +49.70%
Akoya Biosciences
Aug 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.49
Upside: -
Mettler-Toledo International
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,230.74
Upside: +13.75%
Aug 2, 2024
Maintains: Overweight
Price Target: $5 → $6
Current: $6.39
Upside: -6.10%
Jul 31, 2024
Maintains: Overweight
Price Target: $190 → $200
Current: $144.46
Upside: +38.45%
Jul 30, 2024
Maintains: Neutral
Price Target: $105 → $120
Current: $112.56
Upside: +6.61%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.97
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $57.00
Upside: +57.89%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $228.55
Upside: +18.14%